Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Viridian Therapeutics Inc (NASDAQ: VRDN) closed the day trading at $17.98 up 1.24% from the previous closing price of $17.76. In other words, the price has increased by $1.24 from its previous closing price. On the day, 0.52 million shares were traded. VRDN stock price reached its highest trading level at $18.08 during the session, while it also had its lowest trading level at $17.53.
Ratios:
For a better understanding of VRDN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.55 and its Current Ratio is at 18.55. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $27 from $37 previously.
Needham reiterated its Buy rating for the stock on September 11, 2024, while the target price for the stock was revised from $30 to $38.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 27 ’24 when Beetham Thomas W. bought 5,000 shares for $23.41 per share. The transaction valued at 117,050 led to the insider holds 6,000 shares of the business.
Mahoney Stephen F. bought 21,400 shares of VRDN for $499,262 on Sep 27 ’24. The President and CEO now owns 21,400 shares after completing the transaction at $23.33 per share. On Sep 13 ’24, another insider, Fairmount Funds Management LLC, who serves as the Director of the company, bought 1,600,000 shares for $18.75 each. As a result, the insider paid 30,000,000 and bolstered with 3,445,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1424244352 and an Enterprise Value of 883164160. For the stock, the TTM Price-to-Sale (P/S) ratio is 4747.49 while its Price-to-Book (P/B) ratio in mrq is 2.75. Its current Enterprise Value per Revenue stands at 2924.385 whereas that against EBITDA is -3.127.
Stock Price History:
The Beta on a monthly basis for VRDN is 1.06, which has changed by 0.0011273623 over the last 52 weeks, in comparison to a change of 0.21659255 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $11.40. The 50-Day Moving Average of the stock is -6.80%, while the 200-Day Moving Average is calculated to be 1.87%.
Shares Statistics:
Over the past 3-months, VRDN traded about 1.42M shares per day on average, while over the past 10 days, VRDN traded about 1071840 shares per day. A total of 79.18M shares are outstanding, with a floating share count of 70.18M. Insiders hold about 11.40% of the company’s shares, while institutions hold 101.03% stake in the company. Shares short for VRDN as of 1736899200 were 11634941 with a Short Ratio of 8.19, compared to 1734048000 on 9353713. Therefore, it implies a Short% of Shares Outstanding of 11634941 and a Short% of Float of 16.68.
